In:
Science Translational Medicine, American Association for the Advancement of Science (AAAS), Vol. 14, No. 636 ( 2022-03-16)
Abstract:
Indoleamine 2,3-dioxygenase 1 (IDO1) drives immunosuppression in high-grade serous ovarian cancer. Inhibition of IDO1 in combination with chemotherapy has shown limited efficacy in clinical trials. Here, Odunsi et al. treated patients with the IDO1 inhibitor epacadostat and studied the effect on the tumor microenvironment (TME) in tumor biopsies. IDO1 inhibition increased nicotinamide adenine dinucleotide (NAD + ), which reduced T cell function in the TME. Combining epacadostat with purinergic receptor antagonists rescued T cell proliferation in a mouse model of ovarian cancer. These findings highlight the potential downside of IDO1 inhibition and suggest that IDO1 inhibitor therapy will require combination with NAD + signaling blockade.
Type of Medium:
Online Resource
ISSN:
1946-6234
,
1946-6242
DOI:
10.1126/scitranslmed.abg8402
Language:
English
Publisher:
American Association for the Advancement of Science (AAAS)
Publication Date:
2022
Permalink